← Back to Analyst Consensus 
PASG Buy
Passage BIO, Inc.
Current Price —
Implied Upside —
Analysts 9
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Apr 21, 2026 | TD Cowen | downgrade | Buy → Hold | — | 54% |
| Apr 21, 2026 | Chardan Capital | downgrade | Buy → Neutral | — | 47% |
| Apr 21, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Apr 21, 2026 | Wedbush | downgrade | Outperform → Neutral | — | 58% |
| Mar 31, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Mar 4, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Nov 12, 2025 | Chardan Capital | maintain | Buy → Buy | $21 | 47% |
| Aug 14, 2025 | Canaccord Genuity | maintain | Buy → Buy | $67 | 48% |
| Aug 14, 2025 | Guggenheim | maintain | Buy → Buy | $10 | 52% |
| Aug 13, 2025 | Wedbush | maintain | Outperform → Outperform | $40 | 58% |
| Jun 24, 2025 | Chardan Capital | maintain | Buy → Buy | $6 | 47% |
| Mar 4, 2025 | Chardan Capital | maintain | Buy → Buy | $6 | 47% |
| Nov 14, 2024 | Chardan Capital | maintain | Buy → Buy | $7 | 47% |
| Nov 14, 2024 | Canaccord Genuity | maintain | Buy → Buy | $13 | 48% |
| Sep 17, 2024 | Canaccord Genuity | reiterate | Buy → Buy | $13 | 48% |
| Sep 3, 2024 | Rodman & Renshaw | initiate | — → Buy | $7 | 40% |
| May 15, 2024 | Canaccord Genuity | maintain | Buy → Buy | $13 | 48% |
| Mar 5, 2024 | Canaccord Genuity | reiterate | Buy → Buy | $14 | 48% |
| Nov 14, 2023 | Raymond James | maintain | Outperform → Outperform | $5 | 54% |
| Aug 8, 2023 | Chardan Capital | maintain | Buy → Buy | $9 | 47% |
| May 12, 2023 | Raymond James | maintain | Outperform → Outperform | $9 | 54% |
| Dec 15, 2022 | Chardan Capital | maintain | — → Buy | $11 | 47% |
| Nov 11, 2022 | Guggenheim | maintain | — → Buy | $11 | 52% |
| Nov 11, 2022 | Citigroup | maintain | — → Buy | $5 | 54% |
| Nov 8, 2022 | Canaccord Genuity | initiate | — → Buy | $8 | 48% |
| May 17, 2022 | Citigroup | maintain | — → Buy | $10 | 54% |
| May 17, 2022 | Raymond James | maintain | — → Outperform | $10 | 54% |
| Mar 8, 2022 | JP Morgan | downgrade | Overweight → Neutral | $0 | 54% |
| Mar 4, 2022 | Raymond James | maintain | — → Outperform | $24 | 54% |
| Jan 19, 2022 | Goldman Sachs | downgrade | Buy → Neutral | $6 | 54% |
| Jul 1, 2021 | Raymond James | initiate | — → Outperform | $29 | 54% |
| Jun 15, 2021 | BTIG | initiate | — → Buy | $25 | 52% |
| Mar 8, 2021 | Chardan Capital | maintain | — → Buy | $45 | 47% |
| Mar 4, 2021 | Goldman Sachs | upgrade | Neutral → Buy | $30 | 54% |
| Feb 4, 2021 | Guggenheim | initiate | — → Buy | $25 | 52% |
| Jan 4, 2021 | JP Morgan | upgrade | Neutral → Overweight | $35 | 54% |
| Dec 11, 2020 | Citigroup | initiate | — → Neutral | $28 | 54% |
| Aug 14, 2020 | JP Morgan | downgrade | Overweight → Neutral | $25 | 54% |
| Jun 25, 2020 | Goldman Sachs | downgrade | Buy → Neutral | $28 | 54% |
| May 11, 2020 | Chardan Capital | maintain | — → Buy | $32.5 | 47% |
| Mar 25, 2020 | Chardan Capital | initiate | — → Buy | $30 | 47% |
| Mar 24, 2020 | Goldman Sachs | initiate | — → Buy | $27 | 54% |
Price Target Trend
Apr 20, 2026 Latest: $15.5 Oct 25, 2026
EPS Estimates
+1q $-4.06
Lo: $-4.06 Hi: $-4.06
1 analysts 0q $-3.75
Lo: $-3.75 Hi: $-3.75
1 analysts +1y $-11.55
Lo: $-11.55 Hi: $-11.55
1 analysts 0y $-14.08
Lo: $-14.08 Hi: $-14.08
1 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days